ARCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Arcturus Therapeutics Holdings Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.42+0.08 (+0.77%)
Close on Oct 19, 2026
- Market cap
- $296.17M
- P/E (TTM)
- –
- Dividend yield
- –
Arcturus Therapeutics Holdings Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| Collaboration Revenue [Member] | $67.22M | $138.39M | $157.75M | $205.76M | $12.36M | 81.9% | -51.4% |
| Grant Revenue [Member] | $14.81M | $13.92M | $9.05M | $244.00K | – | 18.1% | +6.4% |
By region
From the segment and revenue-disaggregation notes of Arcturus Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.